Renoprotective effect of irbesartan in a rat model of gentamicin-induced nephrotoxicity: Role of oxidative stress

Abstract

BACKGROUND: The renin–angiotensin system (RAS) is essential in renal physiology; however, disturbance of the RAS is one of the chief pathways involved in renal injury. Dysregulation of RAS may result in both glomerular and tubulointerstitial injuries through direct effects of angiotensin II (Ang II) type 1 receptor. Irbesartan and other Ang II blockers have renoprotective effect through reduction of on renal inflammations. Therefore, the aim of the present study was to demonstrate the renoprotective effect of irbesartan on gentamicin-induced nephrotoxicity in rats concerning the oxidative stress.

MATERIALS AND METHODS: Thirty Sprague-Dawley Male rats divided into three groups, Group I (10 rats) treated with distilled water, Group II (10 rats) treated with gentamicin, and Group III (10 rats) treated with gentamicin plus irbesartan for 12 days. Blood urea, serum creatinine, serum malondialdehyde (MDA), superoxide dismutase (SOD), glutathione reductase (GSH), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecules (KIM-1), and cystatin-c were measured in each group.

RESULTS: Irbesartan significantly reduced blood urea, serum creatinine, serum MDA, NGAL, KIM-1, and cystatin-c P < 0.05. Irbesartan significantly increases SOD P < 0.05 without significant effect in elevation of GSH serum levels.

CONCLUSION: Irbesartan has renoprotective effect in attenuation of acute nephrotoxicity through modulation of oxidative stress and antioxidant capacity in rats.

Key words

Anti-oxidant - irbesartan - nephrotoxicities - oxidative stresses

Publication History

Received: 13 October 2018

Accepted: 25 June 2019

Article published online:
07 April 2020

• References

• 1 Al-Naimi MS, Rasheed HA, Hussien NR, Al-Kuraishy HM, Al-Gareeb AI. Nephrotoxicity: Role and significance of renal biomarkers in the early detection of acute renal injury. Journal of Advanced Pharmaceutical Technology & Research 2019;10:95-9.
• 2 Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Di Paola R, Britti D, et al. A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2002;450:67-76.
• 3 Al-Kuraishy HM, Al-Gareeb AL, Rasheed HA. Antioxidant and anti-inflammatory effects of curcumin contribute into attenuation of acute gentamicin-induced nephrotoxicity in rats. Asian J Pharm Clin Res 2019;12:466-8.
• 4 Talebi A, Karimi A, Ouguerram K, Vahidi-Ataabadi N, Eshraghi-Jazi F, Mansouri A, et al. Lack of nephroprotective efficacy of Althaea officinalis flower extract against gentamicin renal toxicity in male rats. Int J Prev Med 2014;5:1360-3.
• 5 Heeba GH. Angiotensin II receptor blocker, losartan, ameliorates gentamicin-induced oxidative stress and nephrotoxicity in rats. Pharmacology 2011;87:232-40.
• 6 Mai HN, Chung YH, Shin EJ, Kim DJ, Jeong JH, Nguyen TT, et al. Genetic depletion of glutathione peroxidase-1 potentiates nephrotoxicity induced by multiple doses of cocaine via activation of angiotensin II AT1 receptor. Free Radic Res 2016;50:467-83.
• 7 Chida R, Hisauchi I, Toyoda S, Kikuchi M, Komatsu T, Hori Y, et al. Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients. Hypertens Res 2015;38:765-9.
• 8 Hsu FY, Lin FJ, Ou HT, Huang SH, Wang CC. Renoprotective effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic patients with proteinuria. Kidney Blood Press Res 2017;42:358-68.
• 9 Hartner A, Cordasic N, Klanke B, Menendez-Castro C, Veelken R, Schmieder RE, et al. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress. Biochim Biophys Acta 2014;1842:558-65.
• 10 Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: A randomized double-blind placebo-controlled crossover study. Diabetes Care 2002;25:1909-13.
• 11 Funakoshi Y, Ichiki T, Takeda K, Tokuno T, Iino N, Takeshita A. Critical role of cAMP-response element-binding protein for angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 2002;277:18710-7.
• 12 Singh AP, Junemann A, Muthuraman A, Jaggi AS, Singh N, Grover K, et al. Animal models of acute renal failure. Pharmacol Rep 2012;64:31-44.
• 13 Al-Kuraishy HM, Al-Gareeb AI. Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect. Journal of advanced pharmaceutical technology & research 2019;10:33-41.
• 14 Gacka E, Życzkowski M, Bogacki R, Paradysz A, Hyla-Klekot L. The usefulness of determining neutrophil gelatinase-associated lipocalin concentration excreted in the urine in the evaluation of cyclosporine a nephrotoxicity in children with nephrotic syndrome. Dis Markers 2016;2016:6872149.
• 15 Thompson SM, Craven RA, Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl 2013;7:241-51.
• 16 Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008;23:853-9.
• 17 Al-Kuraishy HM, Al-Gareeb AI, Al-Naimi MS. Pomegranate protects renal proximal tubules during gentamicin induced-nephrotoxicity in rats. J Contemp Med Sci 2019;5:35-40.
• 18 Al-Kuraishy HM, Al-Gareeb AL, Al-Naimi MS. Pomegranate attenuates acute gentamicin-induced nephrotoxicity in sprague-dawley rats. Asian J Pharm Clin Res 2019;12:1-3.
• 19 Zhao S, Ghosh A, Lo CS, Chenier I, Scholey JW, Filep JG. Nrf2 deficiency upregulates intrarenal angiotensin-converting enzyme-2 and angiotensin 1-7 receptor expression and attenuates hypertension and nephropathy in diabetic mice. Endocrinology 2018;159:836-52.
• 20 Ghafil FA, Al-Zubaidi FA, Almedeny SA. Assessment of nephroprotective role of irbesartan against gentamicin induced nephrotoxicity in rats. Kufa J Vet Med Sci 2012;3:54-60.
• 21 Maquigussa E, Paterno JC, de Oliveira Pokorny GH, da Silva Perez M, Varela VA, da Silva Novaes A, et al. Klotho and PPAR gamma activation mediate the renoprotective effect of losartan in the 5/6 nephrectomy model. Front Physiol 2018;9:1033.
• 22 Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, et al. Angiotensin II enhances AT1-nox 1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, nox 1, and interleukin-18. Am J Physiol Heart Circ Physiol 2012;303:H282-96.
• 23 Beutler KT, Masilamani S, Turban S, Nielsen J, Brooks HL, Ageloff S, et al. Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension 2003;41:1143-50.
• 24 Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
• 25 Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:588-610.
• 26 Nasri H. Antioxidant therapy to ameliorate chronic kidney disease induced by oxidative stress; An updated mini-review. J Prev Epidemiol 2017;2:1-5.
• 27 Al-Kuraishy HM, Al-Gareeb AI, Hussien NR. Synergistic effect of berberine and pentoxifylline in attenuation of acute kidney injury. International Journal of Critical Illness and Injury Science 2019;9:69-76.
• 28 Chander V, Singh D, Tirkey N, Chander H, Chopra K. Amelioration of cyclosporine nephrotoxicity by irbesartan, Aselective AT1 receptor antagonist. Ren Fail 2004;26:467-77.